Physician profile
Bushra Ali
NPI 1861668402
$1,999.45
in general payments reported to CMS, 2019-2025
23 companies · $279 in 2025
The $279 reported for 2025 was more than what 82% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $56.83 · 2021: $149 · 2022: $436 · 2023: $482 · 2024: $169 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $929.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $485.25 | 2021-2025 | Vraylar, Creon |
| Merz North America, INC. | $258.21 | 2019 | |
| Alkermes, INC. | $137.15 | 2022-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $120.52 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $110.79 | 2023 | Austedo, Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $101.19 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.08 | 2022-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $85.05 | 2022-2023 | Auvelity |
| Neurocrine Biosciences, INC. | $73.06 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.73 | 2022-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $66.06 | 2021-2022 | |
| Galderma Laboratories, L.P. | $64.88 | 2019 | |
| Lundbeck LLC | $60.40 | 2022-2025 | Rexulti |
| Allergan, INC. | $48.54 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $38.64 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $35.34 | 2022-2023 | Sertraline Hcl, Loreev Xr |
| Shire North American Group INC | $32.36 | 2019 | |
| Novo Nordisk INC | $25.84 | 2022-2023 | |
| Corium, LLC | $23.30 | 2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $21.98 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.65 | 2020 | |
| Brainsway USA INC | $15.43 | 2022 | |
| Neuronetics, INC. | $9.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bushra Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.